Scientific Alignment on Immune Modulation
The agreement leverages the largest fully synthetic VHH library available — enabling the discovery of high-specificity binders for complex or novel targets.
Antibodies identified through the program are intended to integrate into Cerberus’s KappaLink™ system, which targets the immunoglobulin kappa (Igκ) light chain of naturally circulating antibodies to engage a broad range of FcR+ effector cells against pathogens and tumors of interest. This mechanism offers the potential to support coordinated immune activation across multiple effector pathways — a central goal of Cerberus’s immune-modulating approach.
A Relationship Built on Scientific Insight and Shared Ambition
For Cerberus, a young biotech with a novel therapeutic platform, selecting a discovery partner was about more than technical fit. It was about finding a team with the scientific depth, strategic thinking, and mindset to help shape a complex, early-stage program.
From initial discussions, Isogenica’s team was actively engaged — offering perspective on immunological design challenges, contributing to program direction, and building early trust through transparency and intellectual alignment.
Our conversations with Isogenica revealed more than just technical excellence — they showed us a team that truly listened to our specific needs,” said Thibault Harmand, Ph.D., Acting CEO of Cerberus Therapeutics. “From the start, they offered thoughtful input and multiple strategic proposals to help us design the most effective path to the VHHs we were aiming for. We’ve genuinely valued their partnership.”
“At Isogenica, we bring more than a discovery engine,” said Jessica Kaplunov, Ph.D., Director of Business Development. “We bring a team that’s invested — scientifically, strategically, and personally — in our partners’ success. Cerberus represents exactly the kind of relationship we value: ambitious, rigorous, and grounded in mutual respect.”
